DK2061452T3 - Anvendelse af koffeinsyre og derivater deraf mod cancer - Google Patents

Anvendelse af koffeinsyre og derivater deraf mod cancer

Info

Publication number
DK2061452T3
DK2061452T3 DK07826053.6T DK07826053T DK2061452T3 DK 2061452 T3 DK2061452 T3 DK 2061452T3 DK 07826053 T DK07826053 T DK 07826053T DK 2061452 T3 DK2061452 T3 DK 2061452T3
Authority
DK
Denmark
Prior art keywords
treatment
gleevec
resistant
present
caffeic acid
Prior art date
Application number
DK07826053.6T
Other languages
English (en)
Inventor
Kalpana Sanjay Joshi
Meenakshi Sivakumar
Vilas Sampatrao Wagh
Amit Deshpande
Ankush Gangaram Sarde
Somesh Sharma
Valmik Sopan Aware
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Application granted granted Critical
Publication of DK2061452T3 publication Critical patent/DK2061452T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07826053.6T 2006-09-01 2007-08-20 Anvendelse af koffeinsyre og derivater deraf mod cancer DK2061452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84206006P 2006-09-01 2006-09-01
PCT/IB2007/053308 WO2008026125A2 (en) 2006-09-01 2007-08-20 Anti cancer use of caffeic acid and derivatives

Publications (1)

Publication Number Publication Date
DK2061452T3 true DK2061452T3 (da) 2012-02-13

Family

ID=39015871

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07826053.6T DK2061452T3 (da) 2006-09-01 2007-08-20 Anvendelse af koffeinsyre og derivater deraf mod cancer

Country Status (12)

Country Link
US (1) US20100010002A1 (da)
EP (1) EP2061452B1 (da)
JP (1) JP2010502586A (da)
AT (1) ATE530176T1 (da)
AU (1) AU2007290960B2 (da)
CA (1) CA2662126A1 (da)
DK (1) DK2061452T3 (da)
ES (1) ES2376277T3 (da)
IL (1) IL197262A0 (da)
PT (1) PT2061452E (da)
TW (1) TW200812955A (da)
WO (1) WO2008026125A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722665B2 (en) 2008-11-07 2014-05-13 Council Of Scientific & Industrial Research Cinnamido-pyrrolo[2,1-C][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
CN101456890B (zh) * 2008-12-17 2011-02-02 中南大学 白血病bcr/abl融合基因mRNA的特异性抑制剂
PL2427416T3 (pl) 2009-05-04 2016-09-30 Podstawione związki aromatyczne i ich zastosowania farmaceutyczne
CN103108867A (zh) 2010-02-25 2013-05-15 皮拉马尔企业有限公司 噁二唑化合物及其制备和用途
NZ610851A (en) * 2010-10-27 2015-05-29 Prometic Biosciences Inc Compounds and compositions for the treatment of cancer
WO2013012477A1 (en) * 2011-05-20 2013-01-24 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US20160194718A1 (en) * 2013-05-21 2016-07-07 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators
WO2017161093A1 (en) * 2016-03-17 2017-09-21 Musc Foundation For Research Development Caffeic acid derivatives and uses thereof
US20220370385A1 (en) * 2019-09-17 2022-11-24 Enzene Biosciences Ltd. Compositions for use in inhibiting src kinase and treating and preventing associated disorders
US11878971B2 (en) 2020-12-29 2024-01-23 Huscion Co., Ltd. Piperlongumine-based compound and immuno regulator comprising the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
RU2314096C2 (ru) * 2002-05-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Синергическая фармацевтическая композиция для лечения лейкемии
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
AU2003201062A1 (en) * 2002-07-08 2004-01-23 Council Of Scientific And Industrial Research A pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20060045887A1 (en) 2004-08-25 2006-03-02 Gavish-Galilee Bio Applications Ltd. Mushroom extracts having anticancer activity

Also Published As

Publication number Publication date
US20100010002A1 (en) 2010-01-14
PT2061452E (pt) 2012-01-13
AU2007290960A1 (en) 2008-03-06
JP2010502586A (ja) 2010-01-28
ATE530176T1 (de) 2011-11-15
ES2376277T3 (es) 2012-03-12
TW200812955A (en) 2008-03-16
AU2007290960B2 (en) 2013-04-18
WO2008026125A2 (en) 2008-03-06
EP2061452A2 (en) 2009-05-27
IL197262A0 (en) 2009-12-24
CA2662126A1 (en) 2008-03-06
EP2061452B1 (en) 2011-10-26
WO2008026125A3 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
DK2061452T3 (da) Anvendelse af koffeinsyre og derivater deraf mod cancer
TW200833675A (en) Nicotinamide derivatives
EA200970856A1 (ru) Ингибиторы пути хеджхога
DK2298768T3 (da) 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidinderivater og beslægtede forbindelser til behandling af cancer
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
SE0400284D0 (sv) Novel compounds
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
TW200728307A (en) Novel spirochromanone derivatives
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2009000871A (es) Novedosos inhibidores de transcriptasa inversa de vih.
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
WO2009155121A3 (en) Inhibitors of pi3 kinase
MX2009012847A (es) Analogos dipeptidicos como inhibidores de factores de coagulacion.
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
UA99361C2 (uk) ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR
HK1116161A1 (en) Substituted amide derivatives as protein kinase inhibitors
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
MX2009007482A (es) Agentes antiparasitarios.
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
MX2007013624A (es) Inhibidores de proteina cinasa.
TW200745066A (en) Novel PTP1B inhibitors